| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell and Tumor Biology |
1 Institute of Virology, 2 Department of Pathology, 3 Institute of Biochemistry, and 4 Center for Molecular Medicine Cologne, University of Cologne, Germany
Request for reprints: Herbert Pfister, Institute of Virology, University of Cologne, Fürst-Pückler-Straße 56 50935, Cologne, Germany. Phone: 49-221-4783901; Fax: 49-221-478-3902; E-mail: herbert.pfister{at}medizin.uni-koeln.de.
The cutaneous human papillomavirus (HPV) 8 is clearly involved in skin cancer development in epidermodysplasia verruciformis patients and its early genes E2, E6, and E7 have been implicated in cell transformation in vitro. To examine the functions of these genes in vivo we integrated the complete early region of HPV8 into the genome of DBA/Bl6 mice. To target their expression to the basal layer of the squamous epithelia the transgenes were put under the control of the keratin-14 promoter. Transgenic mice were back-crossed for up to six generations into both FVB/N and Bl6 mouse strains. Whereas none of the HPV8 transgenenegative littermates developed lesions in the skin or any other organ, 91% of HPV8-transgenic mice developed single or multifocal benign tumors, characterized by papillomatosis, acanthosis, hyperkeratosis, and varying degrees of epidermal dysplasia. Squamous cell carcinomas developed in 6% of the transgenic FVB/N mice. Real-time reverse transcription-PCR showed highest expression levels for HPV8-E2, followed by E7 and E6. There was no consistent difference in relative viral RNA levels between healthy or dysplastic skin and malignant skin tumors. Whereas UV-induced mutations in the tumor suppressor gene p53 are frequently detected in human skin carcinomas, mutations in p53 were not observed either in the benign or malignant mouse tumors. Nonmelanoma skin cancer developed in HPV8-transgenic mice without any treatment with physical or chemical carcinogens. This is the first experimental proof of the carcinogenic potential of an epidermodysplasia verruciformisassociated HPV-type in vivo.
Key Words: human papillomavirus epidermodysplasia verruciformis transgenic mice 00-00-21 Melanoma/skin cancers 01-01-14 Animal/in vitro models for carcinogenesis 12-01-01 Human tumor viruses 12-01-02 DNA tumor viruses 12-01-04 Viral transformation and carcinogenesis
This article has been cited by other articles:
![]() |
L. Struijk, E. van der Meijden, S. Kazem, J. ter Schegget, F. R. de Gruijl, R. D. M. Steenbergen, and M. C. W. Feltkamp Specific betapapillomaviruses associated with squamous cell carcinoma of the skin inhibit UVB-induced apoptosis of primary human keratinocytes J. Gen. Virol., September 1, 2008; 89(9): 2303 - 2314. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Bedard, M. P. Underbrink, H. L. Howie, and D. A. Galloway The E6 Oncoproteins from Human Betapapillomaviruses Differentially Activate Telomerase through an E6AP-Dependent Mechanism and Prolong the Lifespan of Primary Keratinocytes J. Virol., April 15, 2008; 82(8): 3894 - 3902. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-S. Gabet, R. Accardi, A. Bellopede, S. Popp, P. Boukamp, B. S. Sylla, J. A. Londono-Vallejo, and M. Tommasino Impairment of the telomere/telomerase system and genomic instability are associated with keratinocyte immortalization induced by the skin human papillomavirus type 38 FASEB J, February 1, 2008; 22(2): 622 - 632. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Nafz, A. Kohler, M. Ohnesorge, I. Nindl, E. Stockfleth, and F. Rosl Persistence of Mastomys natalensis papillomavirus in multiple organs identifies novel targets for infection J. Gen. Virol., October 1, 2007; 88(10): 2670 - 2678. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F.L. O'Shaughnessy, B. Akgul, A. Storey, H. Pfister, C. A. Harwood, and C. Byrne Cutaneous Human Papillomaviruses Down-regulate AKT1, whereas AKT2 Up-regulation and Activation Associates with Tumors Cancer Res., September 1, 2007; 67(17): 8207 - 8215. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Queille, L. Luron, A. Spatz, M. F. Avril, V. Ribrag, P. Duvillard, C. Hiesse, A. Sarasin, J. P. Armand, and L. Daya-Grosjean Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene Carcinogenesis, March 1, 2007; 28(3): 724 - 731. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Michel, A. Kopp-Schneider, H. Zentgraf, A. D. Gruber, and E.-M. de Villiers E6/E7 Expression of Human Papillomavirus Type 20 (HPV-20) and HPV-27 Influences Proliferation and Differentiation of the Skin in UV-Irradiated SKH-hr1 Transgenic Mice J. Virol., November 15, 2006; 80(22): 11153 - 11164. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Muller-Schiffmann, J. Beckmann, and G. Steger The e6 protein of the cutaneous human papillomavirus type 8 can stimulate the viral early and late promoters by distinct mechanisms. J. Virol., September 1, 2006; 80(17): 8718 - 8728. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Semkova, S. Fauser, A. Lappas, N. Smyth, N. Kociok, B. Kirchhof, M. Paulsson, V. Poulaki, and A. M. Joussen Overexpression of FasL in retinal pigment epithelial cells reduces choroidal neovascularization FASEB J, August 1, 2006; 20(10): 1689 - 1691. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. de Koning, W. Quint, L. Struijk, B. Kleter, P. Wanningen, L.-J. van Doorn, S. J. Weissenborn, M. Feltkamp, and J. ter Schegget Evaluation of a Novel Highly Sensitive, Broad-Spectrum PCR-Reverse Hybridization Assay for Detection and Identification of Beta-Papillomavirus DNA. J. Clin. Microbiol., May 1, 2006; 44(5): 1792 - 1800. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Dong, U. Kloz, R. Accardi, S. Caldeira, W.-M. Tong, Z.-Q. Wang, L. Jansen, M. Durst, B. S. Sylla, L. Gissmann, et al. Skin Hyperproliferation and Susceptibility to Chemical Carcinogenesis in Transgenic Mice Expressing E6 and E7 of Human Papillomavirus Type 38 J. Virol., December 1, 2005; 79(23): 14899 - 14908. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Boukamp Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis, October 1, 2005; 26(10): 1657 - 1667. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |